Go Pro
NASDAQ:BOLD

Boundless Bio Q2 2026 Earnings Report

Boundless Bio logo
$2.79 +0.01 (+0.32%)
As of 10:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Boundless Bio EPS Results

Actual EPS
-$1.06
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Boundless Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Boundless Bio Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, August 7, 2026
Conference Call Time
7:00AM ET

Earnings Documents

Boundless Bio Earnings Headlines

Buffett's Final Warning: "The Dollar Is Going to Hell"
In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's happening again this year. And next year. And the year after that. The people who understand this are already moving. In a free presentation I just recorded, I'm revealing what we call "The 2026 AI Gold Rush." The ONE AI-linked asset class the U.S. government has no choice but to fuel… and BlackRock, Goldman Sachs, and 170 public companies are already positioning into it. The same strategy that delivered 12,480% for Mastercard investors since its 2006 IPO. Sitting idle isn't "playing it safe." It's the most expensive decision you'll make this decade.tc pixel
See More Boundless Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Boundless Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Boundless Bio and other key companies, straight to your email.

About Boundless Bio

Boundless Bio (NASDAQ:BOLD) Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

View Boundless Bio Profile